QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.107375v1 319/2/710    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kenakin, T. Articles by Watson, C. Search for Related Content PubMed PubMed Citation Articles by Kenakin, T. Articles by Watson, C.

CELLULAR AND MOLECULAR

Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists

Department of Assay Development (T.K., C.W.) and Department of Biochemical and Analytical Pharmacology (S.J.), GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina

Insurmountable antagonism (maximal response to the agonist depressed) can result from a temporal inequilibrium involving a slow offset orthosteric antagonist or be the result of an allosteric modulation of the receptor. The former mechanism is operative when the antagonist, agonist, and receptors cannot come to proper equilibrium during the time allotted for collection of agonist response (hemi-equilibrium conditions). Allosteric effects (changes in the conformation of the receptor through binding of the allosteric modulator to a separate site) can preclude the agonist-induced production of response, leading to depression of maximal responses. In these cases, the effects on receptor affinity can be observed as well. The first premise of this article is that system-independent estimates of insurmountable antagonist potency can be made with no prior knowledge of molecular mechanism through the use of pA₂ (–log molar concentration of antagonist producing a 2-fold shift of the concentration response curve) measurements The relationship between the pA₂ and antagonist pK_B (–log equilibrium dissociation constant of the antagonist-receptor complex) is described; the former is an extremely close approximation of the latter in most cases. The second premise is that specially designed experiments are required to differentiate orthosteric versus allosteric mechanisms; simply fitting of data to orthosteric or allosteric theoretical models can lead to ambiguous results. A strategy to determine whether the observed antagonism is orthosteric (agonist and antagonist competing for the same binding site on the receptor) or allosteric in nature is described that involves the detection of the hallmarks of allosteric response, namely saturation and probe dependence of effect.

Address correspondence to: Dr. Terry Kenakin, Department of Assay Development, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709. E-mail: terry.p.kenakin{at}gsk.com

This article has been cited by other articles:

				S. Meini, F. Bellucci, C. Catalani, P. Cucchi, A. Giolitti, P. Santicioli, and S. Giuliani Multifaceted Approach to Determine the Antagonist Molecular Mechanism and Interaction of Ibodutant ([1-(2-Phenyl-1R-{[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide) at the Human Tachykinin NK2 Receptor J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 486 - 495. [Abstract] [Full Text] [PDF]

				I. Kalatskaya, Y. A. Berchiche, S. Gravel, B. J. Limberg, J. S. Rosenbaum, and N. Heveker AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties Mol. Pharmacol., May 1, 2009; 75(5): 1240 - 1247. [Abstract] [Full Text] [PDF]

				V. M. Muniz-Medina, S. Jones, J. M. Maglich, C. Galardi, R. E. Hollingsworth, W. M. Kazmierski, R. G. Ferris, M. P. Edelstein, K. E. Chiswell, and T. P. Kenakin The Relative Activity of "Function Sparing" HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? Mol. Pharmacol., March 1, 2009; 75(3): 490 - 501. [Abstract] [Full Text] [PDF]

				C. Quiniou, P. Sapieha, I. Lahaie, X. Hou, S. Brault, M. Beauchamp, M. Leduc, L. Rihakova, J.-S. Joyal, S. Nadeau, et al. Development of a Novel Noncompetitive Antagonist of IL-1 Receptor J. Immunol., May 15, 2008; 180(10): 6977 - 6987. [Abstract] [Full Text] [PDF]

				C. Pinto, D. Papa, M. Hubner, T.-C. Mou, G. H. Lushington, and R. Seifert Activation and Inhibition of Adenylyl Cyclase Isoforms by Forskolin Analogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 27 - 36. [Abstract] [Full Text] [PDF]

				L. M. Ayer, S. M. Wilson, S. L. Traves, D. Proud, and M. A. Giembycz 4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) Is a Selective, Pseudo-Irreversible Orthosteric Antagonist at the Prostacyclin (IP)-Receptor Expressed by Human Airway Epithelial Cells: IP-Receptor-Mediated Inhibition of CXCL9 and CXCL10 Release J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 815 - 826. [Abstract] [Full Text] [PDF]

				T. A. Kohout, Q. Xie, S. Reijmers, K. J. Finn, Z. Guo, Y.-F. Zhu, and R. S. Struthers Trapping of a Nonpeptide Ligand by the Extracellular Domains of the Gonadotropin-Releasing Hormone Receptor Results in Insurmountable Antagonism Mol. Pharmacol., August 1, 2007; 72(2): 238 - 247. [Abstract] [Full Text] [PDF]

				D. J. David, K. C. Klemenhagen, K. A. Holick, M. D. Saxe, I. Mendez, L. Santarelli, D. A. Craig, H. Zhong, C. J. Swanson, L. G. Hegde, et al. Efficacy of the MCHR1 Antagonist N-[3-(1-{[4-(3,4-Difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in Mouse Models of Anxiety and Depression following Acute and Chronic Administration Is Independent of Hippocampal Neurogenesis J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 237 - 248. [Abstract] [Full Text] [PDF]

				C. E. Heise, S. K. Sullivan, and P. D. Crowe Scintillation Proximity Assay as a High-Throughput Method to Identify Slowly Dissociating Nonpeptide Ligand Binding to the GnRH Receptor J Biomol Screen, March 1, 2007; 12(2): 235 - 239. [Abstract] [PDF]